$190 M + contingent payments of another $190 M… Read more…
Net loss of $4.6 M, or $0.16 per diluted share … Read more…
BMTI amends its Augment Bone Graft PMA … Read more…
Net loss of $6.1M, or $0.22 per share Read more…
During the American Academy of Orthopedic Surgeons (AAOS) meeting Read more…
FDA has said its proposed bone-graft device Augment wouldn’t be approved without more information from previous studies. Read more…
The Therapeutic Goods Administration (TGA) has approved a medical device application Read more…
A net loss of $8.2M, or $0.29 per diluted share Read more…
BMTI reported a net loss of $7.8M, or $0.29 per diluted share. Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.